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Abstract
In the course of primary infection with herpes simplex virus 1 (HSV-1), children with inborn
errors of TLR3 immunity are prone to HSV-1 encephalitis (HSE) 1–3. We tested the hypothesis
that the pathogenesis of HSE involves non hematopoietic central nervous system (CNS)-resident
cells. We derived induced pluripotent stem cells (iPSCs) from the dermal fibroblasts of TLR3- and
UNC-93B-deficient patients and from controls. These iPSCs were differentiated into highly
purified populations of neural stem cells (NSCs), neurons, astrocytes and oligodendrocytes. The
induction of IFN-β and/or IFN-γ1 in response to poly(I:C) stimulation was dependent on TLR3
and UNC-93B in all cells tested. However, the induction of IFN-β and IFN-γ1 in response to
HSV-1 infection was impaired selectively in UNC-93B-deficient neurons and oligodendrocytes.
These cells were also much more susceptible to HSV-1 infection than control cells, whereas
UNC-93B-deficient NSCs and astrocytes were not. TLR3-deficient neurons were also found to be
susceptible to HSV-1 infection. The rescue of UNC-93B- and TLR3-deficient cells with the
corresponding wild-type allele demonstrated that the genetic defect was the cause of the poly(I:C)
and HSV-1 phenotypes. The viral infection phenotype was further rescued by treatment with
exogenous IFN-α/β, but not IFN-γ1.Thus, impaired TLR3- and UNC-93B-dependent IFN-α/β
intrinsic immunity to HSV-1 in the CNS, in neurons and oligodendrocytes in particular, may
underlie the pathogenesis of HSE in children with TLR3 pathway deficiencies.
Childhood HSE is a rare, life-threatening, CNS-restricted complication of primary infection
with HSV-1, an almost ubiquitous virus that is typically innocuous 4. Children with HSE are
not unusually susceptible to other infectious agents, including viruses, or even to HSV-1-
related diseases affecting sites other than the CNS 4,5. HSV-1 reaches the CNS from the oral
and nasal epithelium, via the cranial nerves 4. We identified autosomal recessive (AR)
UNC-93B deficiency as the first genetic etiology of childhood HSE 1. UNC-93B is required
for TLR3, TLR7, TLR8 and TLR9 responses 1,6. We then identified AR or autosomal
dominant (AD) deficiencies of TLR3 2,3, TRAF3 7, TRIF 8 and TBK19, revealing that
childhood HSE can be due to the impairment of TLR3 immunity. HSV-1 produces dsRNA
during its replication 10,11 and the dsRNA-sensing TLR3 is expressed and functional in non
hematopoietic (neurons, astrocytes, oligodendrocytes) and hematopoietic (microglia) CNS-
resident cells, which produce IFN-β and IFN-γ upon TLR3 stimulation 12–15 and can be
infected with HSV-1 in vitro 13,16–19. We therefore hypothesized that the pathogenesis of
HSE in patients with TLR3 pathway deficiencies involves impaired TLR3-dependent IFN-
α/β and/or IFN-γ immunity to HSV-1 in the CNS 1,2.
We tested this hypothesis, by generating iPSCs from control, UNC-93B- and TLR3-
deficient dermal fibroblasts (Supplementary Table 1). We first derived and fully
characterized iPSC lines from a healthy child, from a HSE child with AR complete
UNC-93B deficiency 1, and from a patient with AR complete TLR3 deficiency 2, by
reprogramming primary dermal fibroblasts, as previously described 20 (Supplementary Fig.
1 and Methods). A robust stemness and pluripotency profile, karyotypic integrity and
patient-specific origin of the iPSCs were confirmed (Supplementary Fig. 1). Whole-exome
sequencing for one control, one TLR3-deficient and two UNC-93B-deficient iPSC lines
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trevealed more than 99.9% concordance with the corresponding parental fibroblast lines, in
terms of exonic genetic variability (Supplementary Table 2). No synonymous or non
synonymous germline and somatic rare variants of any of the 21 known TLR3 pathway
genes were found in parental fibroblast and iPSC lines, respectively (Supplementary Table
3). We also used two additional, previously described healthy control iPSC lines 21,22 for
subsequent experiments (Supplementary Table 1).
We next induced the differentiation of iPSCs into all major non hematopoietic CNS-resident
cells, including neural stem cells (NSCs), neurons, oligodendrocytes and astrocytes 23,24.
The selective derivation of each individual neural lineage required a multistep iPSC
differentiation approach combined with FACS-mediated cell purification (Fig. 1a). Neural
differentiation of UNC-93B-deficient iPSCs, TLR3-deficient iPSCs, control iPSCs and
control hESCs (H9 line) was induced by dual SMAD inhibition 21,24 (Fig. 1a and
Supplementary Fig. 2a). The resulting polarized columnar neuroepithelial structures
expressed PLZF, ZO1 and PAX6, well known markers of neural rosettes 23. Mechanically
passaged rosettes retained expression of the forebrain marker FOXG1 (Fig. 1b) and yielded
neural precursor cells (NPCs) in the presence of FGF2/EGF (Fig. 1b, Supplementary Fig.
2a). Through differential growth factor treatment and the use of cell type-specific surface
markers in NPC-stage cells, we were able to isolate highly enriched populations of NSCs,
neurons, astrocytes, or oligodendrocyte lineage cells (Fig. 1c, Supplementary Fig. 2b, c).
The purified hESC- and iPSC-derived neuronal populations expressed additional lineage-
specific markers (Supplementary Fig. 3a) and showed the electrophysiological properties of
functional neurons (Supplementary Fig. 3b–e). The identity of the purified GFAP expressing
and O4 expressing glial cell populations was confirmed by global gene expression profiling
(Supplementary Fig. 4a, b). Immunocytochemistry for stage-specific markers was used to
identify the purified O4 “oligodendrocytes” used throughout this study as a mostly immature
(premyelinating) oligodendrocyte population (Supplementary Fig. 4c–e). Quantitative
analysis demonstrated that our preparations of NSCs, neurons, astrocytes and
oligodendrocytes were highly pure (Fig. 1d), and similar gene expression profiles were
obtained for neurons and astrocytes derived from disease-specific and control cell lines
(Supplementary Fig. 5). Our in vitro CNS cell differentiation system therefore constitutes a
reliable platform for the comparative assessment of CNS cell-specific antiviral immunity.
TLR3 expression has been documented in neurons derived in vitro from a human
teratocarcinoma cell line 13, and in primary cells, either in human brain tissues in situ
(neurons 25) or isolated from human brain ex vivo (oligodendrocytes and astrocytes 12,14,26),
but not in human NSCs — self-renewing, multipotent cells responsible for generating
neurons, astrocytes, and oligodendrocytes in the CNS 27. We detected mRNA for key genes
of the TLR3-responsive pathway, including TLR3 and UNC93B1, in all four cell types
tested (Supplementary Fig. 6a–d), whether differentiated from iPSCs or hESCs. We also
detected mRNAs for genes encoding key molecules in the IFN-responsive pathways,
including the receptors for IFN-α/β and IFN-γ, in these cells (Supplementary Fig. 6e–h).
Levels of mRNA for the TLR3- and IFN-responsive pathway genes tested were similar, for
each CNS cell type, between cells differentiated from control iPSCs, control hESCs and
UNC-93B-deficient iPSCs, with the expected exception of UNC93B1, for which mRNA
levels were lower in UNC-93B-deficient cells (Fig. 2a, Supplementary Fig. 6a–d).
We then studied TLR3 responses in the same cells. IFN-γ1 and IFN-β were induced in a
time-dependent manner, by stimulation with the nonspecific TLR3 agonist poly(I:C), a
dsRNA analog, in NSCs, neurons, oligodendrocytes and astrocytes differentiated from
healthy control iPSCs or hESCs, but not in UNC-93B-deficient iPSC-differentiated CNS
cells (Fig. 2b–d, Sup Fig. 6i–l). The induction of NF-κB1, a key IFN-inducing molecule,
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tand that of MX1, a key IFN-inducible molecule, were both impaired in UNC-93B-deficient
oligodendrocytes upon poly(I:C) stimulation (Supplementary Fig. 6m, n). The impaired
response to poly(I:C) in UNC-93B-deficient CNS cells was consistent with our previous
data for UNC-93B-deficient fibroblasts, pointing to a TLR3-dependent response to dsRNA
in these cell types 1. Moreover, impaired poly(I:C)-responsiveness in UNC-93B-deficient
neurons, oligodendrocytes and astrocytes was rescued by transient expression of the human
UNC93B1 gene (Fig. 2b–d). Thus, the UNC-93B-dependent TLR3 pathway is functional in
control human iPSC-derived NSCs, neurons, astrocytes and oligodendrocytes, at least for
the induction of antiviral IFN-γ1 and IFN-β in response to poly(I:C).
We thus set out to compare the response to HSV-1 in UNC-93B-deficient and control iPSC
or hESC-derived CNS cells after infection with HSV-1 and HSV-1-GFP 28. Human NSCs
and astrocytes appeared to be more susceptible to HSV-1 infection than neurons and
oligodendrocytes, as massive HSV-1-GFP replication was observed earlier (Supplementary
Fig. 7 and data not shown). UNC-93B-deficient NSCs and astrocytes derived from two
different iPSC lines also showed high levels of HSV-1-GFP replication, similar to those
observed in the corresponding cell types derived from two control iPSC lines and the control
hESC line (Fig. 3a–c, Supplementary Figs. 8a–c, 9a–c). Treatment of UNC-93B-deficient
and control NSCs and astrocytes with recombinant IFN-α2b or IFN-β, but not IFN-γ1,
decreased HSV-1-GFP replication levels (Supplementary Figs. 8a, c–f, 9a, c–g). Moreover,
treatment with poly(I:C) decreased HSV-1-GFP replication levels in control, but not in
UNC-93B-deficient astrocytes (Supplementary Fig. 9f, 10a–d). By contrast, treatment with
agonists of TLR9 (CpG-A or CpG-C) did not have such an effect (Supplementary Fig. 10a–
d).
When UNC-93B-deficient neurons from the two UNC-93B-deficient iPSC lines were
infected with HSV-1-GFP, HSV-1-GFP replication was faster, reaching higher levels than in
neurons differentiated from four control iPSC lines or one hESC line (Fig. 3a, 3d, 3e,
Supplementary Fig. 11a). The treatment of UNC-93B-deficient neurons with IFN-α2b or
IFN-β, but not IFN-γ1, rescued this phenotype (Supplementary Fig. 11a). Similar results
were obtained with TLR3-deficient neurons that had been differentiated from TLR3-
deficient iPSCs 3,20 (Fig. 3e, Supplementary Fig. 11b). The phenotype of enhanced HSV-1
replication in UNC-93B- and TLR3-deficient neurons was rescued by expression of the
wild-type human UNC93B1 and TLR3 genes, respectively (Fig. 3f, Supplementary Fig.
11b). Finally, higher levels and faster replication of HSV-1-GFP were also observed in
UNC-93B-deficient oligodendrocytes than in oligodendrocytes differentiated from control
iPSCs or hESCs, this phenotype being rescued by treatment with IFN-α2b or IFN-β, but not
IFN-γ1 (Fig. 3a, 3g, Supplementary Fig. 11c, d). This is consistent with our previous
finding of high susceptibility to HSV-1 and VSV in fibroblasts with TLR3 pathway
deficiencies, associated with an impairment of the TLR3-dependent induction of IFN-β and
-γ, which can be rescued more effectively by exogenous IFN-α/β than by IFN-γ1 1,2,3.
We further studied the production of IFNs and inflammatory cytokines in UNC-93B-
deficient and control CNS cells after infection with HSV-1. UNC-93B-deficient neurons,
astrocytes, and oligodendrocytes produced normal amounts of IL-6, as shown by
comparison with control iPSC- or hESC-differentiated CNS cell types (Supplementary Fig.
12a–c). UNC-93B-deficient NSCs and astrocytes seemed to produce detectable but lower
levels of IFN-γ1 than the control cells tested (Supplementary Fig. 12d, e), suggesting that
UNC-93B-independent, TLR3-independent partially compensatory pathways may be
involved in triggering IFN responses to HSV-1 in human NSCs and astrocytes. The
induction of IFN-β or IFN-γ1 was readily observed in control iPSC- or hESC-differentiated
neurons or oligodendrocytes, but was greatly impaired in UNC-93B-deficient neurons and
oligodendrocytes, respectively (Supplementary Fig. 12f, g). The induction of MX1 was also
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timpaired in UNC-93B-deficient oligodendrocytes upon HSV-1 infection (Supplementary
Fig. 12h). Thus, neurons and oligodendrocytes lacking UNC-93B may be highly vulnerable
to HSV-1 infection because of an impairment of the cell-autonomous IFN-α/β or –γ
immunity.
Our findings suggest that neurons and oligodendrocytes provide strong, intrinsic protective
anti-HSV-1 immunity in the CNS, via an intact TLR3 pathway. Although NSCs and
astrocytes lacking UNC-93B are not more susceptible to HSV-1 infection than control cells
in vitro, they may play a role in protective anti-HSV-1 immunity in the CNS in vivo. Indeed,
mouse astrocytes rely on TLR3 to control HSV-2 29. Hematopoietic cell-derived microglial
cells, which also express TLR3 and can be infected with HSV-1 12,14,17, may also contribute
to HSE. CNS-intrinsic mechanisms are thus vital for the control of HSV-1 in the course of
primary infection in childhood. These new findings, adding to our previous results
indicating that most leukocytes and keratinocytes from HSE patients with TLR3 pathway
deficiencies respond normally to stimulation with poly(I:C) or HSV-1 2,3,9, are remarkably
consistent with the CNS-restricted pattern of lesions during childhood HSE, with no
disseminated disease. Human non hematopoietic cells may be the key to survival during the
course of primary infection, extending the concepts of host defense beyond innate and
adaptive hematopoietic immunity, to non hematopoietic ‘intrinsic’ immunity 30.
Methods
Cell culture
Fibroblasts obtained from an UNC-93B-deficient patient, a TLR3-deficient patint and a
healthy control were maintained in DMEM supplemented with 10% fetal calf serum (FCS),
2 mM L-glutamine and penicillin (50 U/ml)/streptomycin (50 mg/ml) (hFib media). The
patients resided in France, where they were followed up and informed consent was obtained,
in accordance with local regulations, with institutional review board (IRB) approval. The
experiments described here were conducted in the United States, in accordance with local
regulations and with the approval of the IRB of The Rockefeller University, The Harvard
Medical School and The Sloan-Kettering Institute for Cancer Research. Induced pluripotent
stem cells (iPSCs) and human embryonic stem cells (hESCs; line H9 (WA-09, XX, P40–55)
were maintained on CF1-irradiated MEFs (iMEFs, Globalstem Inc) in hESC medium (hESC
media) consisting of DMEM/F12 (Invitrogen) supplemented with 20% Knockout Serum
(KOSR) (Invitrogen), 10 ng/ml basic fibroblast growth factor (bFGF, Gemini Bio-Products),
1 mM L-glutamine (Invitrogen), 100 μM non essential amino acids, 100 μM 2-β-
mercaptoethanol (Sigma-Aldrich) and penicillin (50 U/ml)/streptomycin (50 mg/ml). iPSCs
were stimulated to differentiate into embryoid bodies (EB) by culture in bFGF-free hESC
medium, without coculture with feeder cells, on non adherent Petri dishes, as previously
described 31.
Neural induction and neural subtype specification
MS5 stromal cells were grown in MEM medium supplemented with 10% FBS and 2 mM L-
glutamine 32. The neural differentiation of hESCs and iPSCs was induced as previously
described 33, but in the presence of Noggin (R&D Systems) and SB431542 (Stemgent) from
days 3 to 10 of differentiation (dual-SMAD inhibition 21), to increase the efficiency of
rosette formation. Rosettes were harvested mechanically, starting at day 8 of differentiation,
and were replated under feeder-free conditions on dishes coated with 10 μg/ml polyornithine
(Sigma), 2 μg/ml laminin (Cultrex), and 1 μg/ml fibronectin (Fisher) (Po/Lam/FN), in N2
medium supplemented with Sonic C25 II (20 mg/ml; R&D Systems), ascorbic acid (AA, 0.2
mM; Sigma) and BDNF (20 ng/ml; R&D Systems). Rosettes were allowed to proliferate for
a further five days and were then replated, dissociated in Ca2/Mg2-free HBSS and replated
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tagain. Emerging clusters of NPCs were harvested for further proliferation or neural subtype
specification. For the generation of neural stem cells and neurons, NPCs were maintained in
N2 medium supplemented with EGF (20 ng/ml) and FGF2 (20 ng/ml) (R&D Systems) and
B-27 supplement without vitamin A (1:100, Invitrogen). For the generation of astrocytes,
NPCs were allowed to proliferate and were passaged in the presence of EGF and FGF2 for
40 to 60 days and then exposed to N2 medium containing 5% FBS for an additional 15 to 20
days. For the generation of oligodendrocytes, emerging clusters of NPCs were cultured in
N2 medium supplemented with Sonic C25II (125 ng/ml), FGF8 (100 ng/ml; R&D Systems),
BDNF (20 ng/ml) and ascorbic acid (AA, 0.2 mM) for 50 to 70 days.
Plasmids and vectors
The polycistronic lentiviral pHAGE–STEMCCA–LoxP vector, carrying the OCT4, SOX2,
KLF4, and C-MYC reprogramming factor genes, has been described elsewhere 34. Human
UNC93B1 cDNA was amplified from existing cDNA sequences with the following primers:
forward 5′-ATAATATGGCCACACATATGGAGGCGGAGCCG-3′ and reverse 5′-
GTTGATTAGGATCTATCGTCACTGCTCCTCCGG-3′. The amplified product was
inserted downstream from the IRES in a pHAGE2-EF1a-DsRedExpress-IRES-W lentiviral
vector (available from the Mostoslavsky laboratory), with the In-Fusion Advantage PCR
cloning Kit (Clontech).
Lentivirus production
Lentiviruses containing STEMCCA or pHAGE2-EF1a-DsRedExpress-IRES-UNC93B1
were produced with a five-plasmid transfection system, in 293T packaging cells, by a
slightly modified version of a previously described method 35. Briefly, 293T cells were
transfected with STEMCCA or pHAGE2-EF1a-DsRedExpress-IRES-UNC93B and four
plasmids encoding the packaging proteins Gag-Pol, Rev, Tat and the G-protein of the
vesicular stomatitis virus (VSVG), in the presence of the Trans-IT® 293 transfection reagent
(Mirus). Viral supernatants were collected every 12 hours, on two consecutive days, starting
48 hours after transfection, and viral particles were concentrated by ultracentrifugation at
49,000 g for 1.5 hours at 4°C.
Lentiviral infection and human iPSC generation
We infected 105 fibroblasts derived from patients or controls with the concentrated
polycistronic STEMCCA lentiviral vector and then cultured them at 37°C, under an
atmosphere containing 5% CO2, in 2 ml of hFib medium supplemented with 5 μg/ml
protamine sulfate, for 24 hours. One day after infection, the viral supernatant was removed
and the cells were cultured for 72 hours in hFib medium. They were then transferred onto
iMEFs and the medium was replaced with hESC medium. iPSC colonies with an ESC-like
morphology were mechanically isolated four to five weeks after infection.
Immunostaining
Cells were fixed by incubation in 4% paraformaldehyde for 30 minutes and permeabilized
by incubation with 0.2% Triton X-100 for 30 minutes. Cells were stained in blocking buffer
(3% BSA; 5% goat serum) with primary (or conjugated) antibodies at 4°C overnight,
washed and stained with secondary antibodies and 1 μg/ml Hoechst 33342 in blocking
buffer for 3 hours at 4°C, in the dark. Primary OCT4 and NANOG antibodies (Abcam,
Cambridge, MA) were used at a concentration of 0.5 μg/ml, and an Alexa Fluor 555-
conjugated anti-rabbit IgG 555 (Invitrogen) was used as the secondary antibody (1:2000).
The following conjugated antibodies — TRA-1-60-Alexa Fluor 647, TRA-1-81-Alexa Fluor
488, SSEA-4-Alexa Fluor 647, and SSEA-3-Alexa 488 (Millipore, Billerica, MA) — were
used at a dilution of 1:100. FoxG1 antibody was a gift from Dr. S. A. Anderson. Nestin
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tantibody was obtained from Neuromics, Tuj1antibody from Covance, O4 from Millipore,
GFAP from Dako, PLZF from Calbiochem, and ZO-1from Zymed. Images were acquired
with a Pathway 435 bioimager equipped with a 10x objective (BD Biosciences, San Jose,
CA).
Whole-exome sequencing and analysis
DNA (3 μg) was extracted from cells and sheared with a Covaris S2 Ultrasonicator
(Covaris). An adapter-ligated library was prepared with the TruSeq DNA Sample Prep Kit
(Illumina). Exome capture was performed with the SureSelect Human All Exon 50 Mb kit
(Agilent Technologies). Paired-end sequencing was performed on an Illumina HiSeq 2000
(Illumina), generating 100-base reads. The sequences were aligned with the human genome
reference sequence (hg19 build), with BWA aligner 36. Downstream processing was carried
out with the Genome Analysis Toolkit (GATK) 37, SAM tools 38 and Picard Tools (http://
picard.sourceforge.net). Variant calls were made with GATK UnifiedGenotyper. All calls
with a Phred-scaled SNP quality ≤20 were filtered out. GATK VariantEval was used to
compare the call sets for fibroblasts and iPSCs.
FACS-mediated cell purification
Cells were dissociated with Accutase (Innovative Cell Technologies Inc.) and subjected to
FACS with O4 (1:300; Millipore), CD44 FITC (2 μl/106 cells; Abcam), and EGFR PE (10
μl/106 cells; Abcam) antibodies, on a FACS Aria II machine (BD).
Karyotype analysis
Karyotyping and G-banding were performed blind, by Cell Line Genetics.
Mutation analysis
Whole-genome DNA was isolated from fibroblasts and iPSCs with the QiAMP DNA Kit
(Qiagen). Exon 8 of the UNC93B1 gene was amplified with the forward primer
GCGTGGCTTTGTGCTGAGAG and the reverse primer
CAGGAGGGGGATATTTGGGA. Reaction products were purified with the QIAquick PCR
purification kit (Qiagen) and sequenced by the DF/HCC DNA Sequencing Facility. The
results were analyzed with Sequencher 4.8 software (Gene Codes Corporation).
Microarray analysis
Total RNA was extracted with Trizol reagent (Invitrogen). RNA was collected from
astrocytes and from CD44−/EGFR− neurons differentiated from control hESCs or
UNC-93B-deficient iPSCs. The RNA was then processed by the MSKCC Genomic core
facility and hybridized with Illumina human HT-12 oligonucleotide arrays. Gene expression
analysis was carried out with the Partek Genomics Suite: following quantile normalization,
all the genes displaying differential expression (FDR of 0.05, fold change of at least ± 2)
with respect to hESC (total of 7210 genes) in each population were visualized by clustering.
Raw data for the microarray analyses performed in this study are available from the public
repository of GEO DataSets (accession no. GSE40593).
Electrophysiology
Whole-cell current clamp recordings were performed at room temperature (23–24°C) in a
Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA), as previously
described 39,40. Neurons were identified under a Nikon microscope equipped with a 4×
objective and a 40× water immersion objective. Cells were continuously perfused with
freshly prepared extracellular solution containing 126 mM NaCl, 26 mM NaHCO3, 3.6 mM
KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2 mM CaCl2 and 17 mM glucose, and the solution
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twas saturated with 95% O2 – 5% CO2. The intracellular solution contained 135 mM
potassium gluconate, 5 mM NaCl, 10 mM HEPES, 0.5 mM EGTA, 3 mM potassium ATP,
0.2 mM sodium GTP and 10 mM sodium phosphocreatine. The pH was adjusted to 7.3 with
KOH, and the osmolarity of the solution was ~290 mOsm. Input resistance was calculated
from the voltage response elicited by the intracellular injection of a depolarizing (+10 or +20
pA) current pulse. Current steps were applied for 1 s to evoke action potentials. Liquid
junction potentials were calculated and corrected off-line. Data were analyzed with Clampfit
(Molecular Devices) and SigmaPlot 11 (Systat Software, Chicago, IL) and are presented as
means ± SEM.
Reverse transcription-quantitative PCR (RT-qPCR)
For analysis of the expression profiles of key genes involved in stem cell properties and
pluripotency, total RNA was extracted with the mirVana™ RNA isolation kit (Ambion). We
reverse-transcribed 100 ng of total RNA to generate cDNA, in qScript cDNA Supermix
(Quanta). Quantitative real-time PCR was then performed in an AB 7500 Real-Time PCR
system (Applied Biosystems), with the PowerSYBR Green PCR Master Mix (Applied
Biosystems). The results were analyzed with SDSv1 Software and normalized with respect
to β-actin gene expression. Expression levels were determined by the ddCT method and are
expressed relative to those in the individual parental cell lines. The primer sequences used
have been described elsewhere 41. We assessed the expression levels of genes of the TLR3
and IFN pathways and of the genes for IFN-β, IFN-γ, NF-κB and MX1, by extracting total
RNA from NSCs, neurons, oligodendrocytes and astrocytes. RNA was reverse-transcribed
directly, with oligo-dT, to determine mRNA levels for TLR3 and IFN pathway genes and
for IFN-β, IFN-γ, NF-κB and MX1. RT-qPCR was performed with Applied Biosystems
Assays-on-Demand™ probe/primer combinations and 2 x universal reaction mixture, in an
ABI 7500 Fast Real-Time PCR System. The β-glucuronidase (GUS) gene was used for
normalization. Results are expressed according to the ΔΔCt method, as described by the
manufacturer.
TLR3 agonists and viral stimulation
We used a synthetic analog of dsRNA, (polyinosinepolycytidylic acid (poly(I:C);
Amersham), a TLR-3 agonist, at a concentration of 25 μg/ml. After incubation with or
without poly(I:C) for 2, 4 or 6 hours, cells were collected in Trizol for RNA extraction. For
HSV-1 infection, we used the KOS-1 strain, at a multiplicity of infection (MOI) of 1. A
GFP-expressing HSV-1 (HSV-1-GFP 281) was used at various MOI to infect fibroblasts,
NSCs, neurons, oligodendrocytes and astrocytes.
Cytokine determinations
The production of IFN-α, -β and -γ and of IL-6 was assessed by ELISA. Separate ELISAs
were carried out for each of IFN-α (AbCys SA, Paris, France), IFN-β (TFB, Fujirebio, Inc.,
Tokyo, Japan) and IL-6 (Sanquin, Amsterdam, the Netherlands), according to the kit
manufacturers’ instructions. The IFN-γ ELISA was developed in the laboratory, as
previously described 42.
HSV-1-GFP infection and quantification
For HSV-1 GFP infection, 104 SV40-transformed fibroblasts, NSCs, neurons,
oligodendrocytes or astrocytes were plated in individual wells of 96-well plates and infected
with HSV-1-GFP, at various MOI, in a medium appropriate for the cell type concerned.
Cells were incubated for two hours, then washed and incubated in 100 μl of culture medium.
HSV-1-GFP titers were determined by calculating the 50% end point (TCID50), as described
by Reed and Muench, after the inoculation of Vero cell cultures in 96-well plates. The GFP
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tfluorescence of the samples was quantified at the 2 h, 8 h, 18 h and 24 h time points. For
assays of cell protection upon viral stimulation, cells were treated with IFN-α2b (104 IU/ml,
Schering-Plough, USA), IFN-β (104 IU/ml, PBI Interferonsource, USA), IFN-γ1 (2.5 μg/
ml, R&D Systems), poly(I:C) (25 μg/ml), CpG-A (5 μg/ml, Dynavax Technologies,
Berkeley, CA) or CpG-C (5 μg/ml, Dynavax Technologies, Berkeley, CA), for 18 hours
before infection for fibroblasts and 36 hours before infection for neurons, oligodendrocytes,
NSCs and astrocytes, as appropriate.
Statistical tests
Mean values were compared between control cells and cells from the patient, by ANOVA
and/or Student’s t-tests, as implemented in the procedures PROC TTEST and PROC
ANOVA of SAS version 9.1 (SAS institute, Cary, NC, USA). ANOVA was carried out to
compare the means of more than two groups. When significant, ANOVA was followed by t
tests for pairwise comparisons (in particular, Dunnett’s t tests comparing the patient with
each of the controls).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Derivation and purification of CNS cells
a- Schematic diagram of the differentiation and purification protocols used. b-
Representative phase-contrast images showing the morphology of the hPSCs, neural rosettes
and NPC clusters, from healthy control hESCs, healthy control iPSCs, and UNC-93B−/−
iPSCs. Immunocytochemistry analysis revealed the expression of rosette markers (PLZF/
ZO1) and a forebrain marker FOXG1. c- Characterization of UNC-93B−/− iPSC-derived
CNS cell types: Upper panels: phase-contrast images illustrating the characteristic
morphology of each type of neural cell; Lower panels: immunofluorescence analysis for
markers of neural stem cells (nestin), neurons (Tuj1), oligodendrocyte progenitor cells (O4)
and astrocytes (GFAP). d-Quantification of marker expression for each neural cell type
derived from control hESCs, UNC-93B−/− iPSCs, and control iPSCs (error bars = SEM). *
Scale bars in b- correspond to 100 μm; those in c- correspond to 50 μm, except for O4
staining (100 μm).
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tFigure 2. UNC-93B-dependent IFN responses to TLR3 in neurons and glial cells
a- UNC93B1 mRNA levels in CNS cells differentiated from hESCs from a healthy control
(C+ (hESC)) and iPSCs from a healthy control (C+ (iPSC)) and an UNC-93B-deficient
patient (UNC-93B−/−). b-, c- IFN-β (b-) or IFN-γ1 (c-) mRNA induction, after six hours of
poly(I:C) stimulation, in neurons (b-) or oligodendrocytes (c-) differentiated from one
healthy control hESC line, one healthy control iPSC line, and in UNC-93B−/− neurons (b-)
or oligodendrocytes (c-), without lentiviral infection, or after infection with a lentivirus
containing human WT UNC93B1 (UNC-93B−/− + UNC93B1) or a mock construct
(UNC-93B−/− + mock). d- IFN-β (upper panel) or IFN-γ1 (lower panel) mRNA induction,
after four (upper panel) or six (lower panel) hours of poly(I:C) stimulation, in astrocytes
differentiated from hESCs from a healthy control, in UNC-93B−/− astrocytes, without
lentiviral infection, or after infection with a lentivirus containing human WT UNC93B1
(UNC-93B−/− + UNC93B1) or a mock construct (UNC-93B−/− + mock). In a- to d-, Mean
values ± SEM were calculated from three (a-) or two (b–d) independent experiments, each
carried out in duplicate. ANOVA was performed for data shown in a-. When significant,
Dunnett t tests were performed for 2X2 comparisons, significant results are indicated in
corresponding panels (* p<0.05, ** p<0.01).
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tFigure 3. High HSV-1 susceptibility in UNC-93B-deficient neurons and oligodendrocytes
24 hours of infection with HSV-1-GFP, at a multiplicity of infection of 1, was performed in
experiments shown. a- GFP expression in CNS cells differentiated from UNC-93B−/− iPSCs
or from hESCs from a healthy control (C+) was visualized by fluorescence microscopy.
Phase-contrast photomicrographs from the same view are also shown. b-, c-, d- GFP
expression in NSCs (b-), astrocytes (c-) and neurons (d-) differentiated from UNC-93B−/−
iPSCs, from hESCs from a healthy control (C+ (hESC)) and one to two iPSC lines each from
up to three healthy controls (C+ (iPSC)), was assessed with a fluorescence plate reader. The
difference in GFP intensity between HSV-1-GFP-infected cells and uninfected cells is
shown. e- GFP expression in neurons differentiated from two lines of UNC-93B−/− iPSCs,
one line of TLR3−/− iPSCs, one or two iPSC lines each from three healthy controls, or from
one C+ hESCs line. f- GFP expression, in neurons from one C+ iPSC line, in UNC-93B−/−
neurons, without lentiviral infection, or after infection with a lentivirus containing human
WT UNC93B1 (UNC-93B−/− + UNC93B1) or a mock construct (UNC-93B−/− + Mock). g-
GFP expression in oligodendrocytes differentiated from UNC-93B−/− iPSCs, from a C+
hESC line and a C+ iPSC line. Error bars = SEM, calculated from two to three experiments,
from the C+ hESC, from the C+ iPSC lines and from the UNC-93B−/− lines, each studied in
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ttriplicate (b-, c-, d-, e- and g-); or from one experiment carried out in triplicate,
representative of two independent experiments (f-). ANOVA was performed for the data
shown in b- to g-. When significant, Dunnett t tests were performed for 2X2 comparisons,
significant results are indicated in corresponding panels (* p<0.05, ** p<0.01, *** p<0.001).
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